ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Synthetic Biologics Discontinues Study of SYN-010 in IBS-C Patients
October 12, 2020Synthetic Biologics has announced the results of a planned interim futility analysis of the investigator-sponsored Phase 2b clinical study of SYN-010 being conducted by Cedars-Sinai Medical Center (CSMC). -
Synthetic Biologics Announces Positive FDA Meeting on SYN-004 Development
November 29, 2018Synthetic Biologics announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss development of SYN-004 ...... -
Synthetic Biologics’ SYN-004 secures FDA breakthrough therapy status
May 16, 2017Synthetic Biologics has secured breakthrough therapy designation for SYN-004 (ribaxamase) from the US Food and Drug Administration (FDA) to treat Clostridium difficile infection (CDI).
Pharma Sources Insight January 2025
